Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.
Vivus announced second-quarter losses much worse than anyone expected. It took the first public comments from incoming CEO Tony Zook to sustain hopes for a turnaround.
Vivus says its new diet drug Qsymia is now available in 8,000 retail pharmacies, putting it closer to patients. Arena Pharmaceuticals' Belviq is finally on the market, and scripts are coming in. But this new generation of weight-loss pills still faces an uphill climb--despite the tantalizing size of the market.
The AMA's decision to classify obesity as a disease is a direct attempt to persuade biopharma companies to develop new therapies by making it harder for payers to decline coverage while applying pressure on the FDA to approve more drugs faster. And that could provide a serious incentive for the obesity therapies already in development while making the preclinical work in the field more attractive to Big Pharma companies--which have largely avoided the field after witnessing repeated marketing debacles for unsafe meds. Read more >>
The long-awaited battle between two weight loss drugs is ready to begin. With its launch for Belviq delayed by the DEA, Arena has had to sit back and watch competitor Vivus pass it by with its own weight-loss drug. Now, nearly a year after the FDA cleared Belviq for approval, investors will get the chance to see if it can outperform its underwhelming competitor, Qsymia.
Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged investors. Shares rose 9.7% to $13.21, the biggest one-day increase since Dec. 17, Bloomberg reported.
The DEA has made its decision on Belviq, the weight-loss drug that's been sitting on Arena's launching pad since its FDA approval last June. Belviq is now officially a Schedule IV controlled substance, and Arena can fire up its engines for a launch next month.
Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.
Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.
Just in time for New Year's resolutions, The Financial Times rounds up the latest on a new generation of obesity drugs.